Cargando…

Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients

Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation, replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase proteolytic activity are associated with aneuploidy, tumorigenesis, and disease progression. Since genomic instability an...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiess, Birgit, Kleiner, Helga, Flach, Johanna, Fabarius, Alice, Saussele, Susanne, Hofmann, Wolf-Karsten, Seifarth, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196950/
https://www.ncbi.nlm.nih.gov/pubmed/32253454
http://dx.doi.org/10.1007/s00277-020-04007-4
_version_ 1783528794008584192
author Spiess, Birgit
Kleiner, Helga
Flach, Johanna
Fabarius, Alice
Saussele, Susanne
Hofmann, Wolf-Karsten
Seifarth, Wolfgang
author_facet Spiess, Birgit
Kleiner, Helga
Flach, Johanna
Fabarius, Alice
Saussele, Susanne
Hofmann, Wolf-Karsten
Seifarth, Wolfgang
author_sort Spiess, Birgit
collection PubMed
description Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation, replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase proteolytic activity are associated with aneuploidy, tumorigenesis, and disease progression. Since genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML), we have comparatively examined separase proteolytic activity in TKI-treated chronic phase CML. Separase proteolytic activity was analyzed on single cell level in 88 clinical samples and in 14 healthy controls by a flow cytometric assay. In parallel, BCR-ABL1 gene expression and replication fork velocity were measured by qRT-PCR and DNA fiber assays, respectively. The separase activity distribution (SAD) value indicating the occurrence of MNCs with elevated separase proteolytic activity within samples was found to positively correlate with BCR-ABL1 gene expression levels and loss of MMR (relapse) throughout routine BCR-ABL1 monitoring. Analyses of CD34(+) cells and MNCs fractionized by flow cytometric cell sorting according to their separase activity levels (H- and L-fractions) revealed that CD34(+) cells with elevated separase activity levels (H-fractions) displayed enhanced proliferation/viability when compared with cells with regular (L-fraction) separase activity (mean 3.3-fold, p = 0.0011). BCR-ABL1 gene expression positivity prevailed in MNC H-fractions over L-fractions (42% vs. 8%, respectively). Moreover, expanding CD34(+) cells of H-fractions showed decreased replication fork velocity compared with cells of L-fractions (p < 0.0001). Our data suggests an association between high separase activity, residual BCR-ABL1 gene expression, and enhanced proliferative capacity in hematopoietic cells within the leukemic niche of TKI-treated chronic phase CML. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00277-020-04007-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7196950
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-71969502020-05-05 Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients Spiess, Birgit Kleiner, Helga Flach, Johanna Fabarius, Alice Saussele, Susanne Hofmann, Wolf-Karsten Seifarth, Wolfgang Ann Hematol Original Article Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation, replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase proteolytic activity are associated with aneuploidy, tumorigenesis, and disease progression. Since genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML), we have comparatively examined separase proteolytic activity in TKI-treated chronic phase CML. Separase proteolytic activity was analyzed on single cell level in 88 clinical samples and in 14 healthy controls by a flow cytometric assay. In parallel, BCR-ABL1 gene expression and replication fork velocity were measured by qRT-PCR and DNA fiber assays, respectively. The separase activity distribution (SAD) value indicating the occurrence of MNCs with elevated separase proteolytic activity within samples was found to positively correlate with BCR-ABL1 gene expression levels and loss of MMR (relapse) throughout routine BCR-ABL1 monitoring. Analyses of CD34(+) cells and MNCs fractionized by flow cytometric cell sorting according to their separase activity levels (H- and L-fractions) revealed that CD34(+) cells with elevated separase activity levels (H-fractions) displayed enhanced proliferation/viability when compared with cells with regular (L-fraction) separase activity (mean 3.3-fold, p = 0.0011). BCR-ABL1 gene expression positivity prevailed in MNC H-fractions over L-fractions (42% vs. 8%, respectively). Moreover, expanding CD34(+) cells of H-fractions showed decreased replication fork velocity compared with cells of L-fractions (p < 0.0001). Our data suggests an association between high separase activity, residual BCR-ABL1 gene expression, and enhanced proliferative capacity in hematopoietic cells within the leukemic niche of TKI-treated chronic phase CML. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00277-020-04007-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-06 2020 /pmc/articles/PMC7196950/ /pubmed/32253454 http://dx.doi.org/10.1007/s00277-020-04007-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Spiess, Birgit
Kleiner, Helga
Flach, Johanna
Fabarius, Alice
Saussele, Susanne
Hofmann, Wolf-Karsten
Seifarth, Wolfgang
Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title_full Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title_fullStr Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title_full_unstemmed Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title_short Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
title_sort separase activity distribution can be a marker of major molecular response and proliferation of cd34(+) cells in tki-treated chronic myeloid leukemia patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196950/
https://www.ncbi.nlm.nih.gov/pubmed/32253454
http://dx.doi.org/10.1007/s00277-020-04007-4
work_keys_str_mv AT spiessbirgit separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT kleinerhelga separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT flachjohanna separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT fabariusalice separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT sausselesusanne separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT hofmannwolfkarsten separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients
AT seifarthwolfgang separaseactivitydistributioncanbeamarkerofmajormolecularresponseandproliferationofcd34cellsintkitreatedchronicmyeloidleukemiapatients